Famotidine pills

To favorites
Famotidine Famotidine does not affect the content of gastrin in the blood serum on an empty stomach or after a meal, does not affect gastric emptying, exocrine pancreatic function, blood flow in the liver and portal system.
Active substance:Famotidine
Pharmacological group:Gastrointestinal medications
Country of origin:Russia
In stock
In stock
In stock

Instructions for Famotidine pills

English product name

Release form
tab, shell, 20 mg: 7, 10, 14, 20, 21, 28, 30, 40, 42, 56, 60, 70, 80, 100, 140 or 200 pcs
tabbed shell 40 mg: 7, 10, 14, 20, 21, 28, 30, 40, 42, 56, 60, 70, 100 or 140 pcs

Shell-coated tablets 1 tab.

ATC codes
A02BA03 Famotidine

Clinical-pharmacological groups / Group affiliation
Histamine H<SUB>2</SUB> receptor blocker. Antiulcer preparation

Active substance

Pharmacotherapy group Famotidine:

Histamine H2 receptor blocker

Storage Conditions
List B. In a dry, light-proof place at a temperature not higher than 25°C. Store in a place not accessible to children.

Best before date
The shelf life is two years.

Pharmacological effect Famotidine:

H2-histamine receptor blocker, Generation III. Inhibits the basic and histamine-, gastrin- and acetylcholine-stimulated production of hydrochloric acid. At the same time as the production of hydrochloric acid decreases and the pH increases, pepsin activity decreases. It does not significantly change the concentration of gastrine in the plasma. Weakly inhibits the cytochrome P450 oxidase system in the liver. After ingestion, the action begins after 1 hour, reaches the maximum within 3 hours. The duration of action of the drug at a single dose depends on the dose and is from 12 to 24 hours.

  • Testimony Famotidine:
  • Treatment and prevention of recurrence of gastric and duodenal ulcer disease;
  • Treatment and prophylaxis of symptomatic stomach and duodenal ulcers (associated with the use of non-steroidal anti
  • inflammatory drugs (NSAIDs), stressful, post-operative ulcers);
  • erosive gastroduodenitis;
  • functional dyspepsia associated with increased secretory function of the stomach (including heartburn, acid burp);
  • reflux esophagitis;
  • Zollinger-Ellison syndrome;
  • Prevention of recurrent haemorrhage from the upper gastrointestinal tract (GI);
  • prevention of gastric juice aspiration in general anesthesia (Mendelssohn syndrome).

Method of use, course and dosage Famotidine:

Inside without chewing, sucking enough water.
In the case of gastric and duodenal ulcer in the exacerbation phase, symptomatic ulcers, erosive gastroduodenitis is usually prescribed twenty mg twice a day or 40 mg once a day per night. If necessary, the daily dose can be increased to 80-160 mg. The course of treatment is 4-8 weeks.
In the case of dyspepsia associated with increased secretory function of the stomach, twenty mg are prescribed once - twice daily.
To prevent recurrence of peptic ulcer of stomach and duodenum: 20 mg once before bed.
For reflux-esophagy - 20-40 mg twice a day for 6-12 weeks.
For Zollinger-Ellison syndrome, the dose and duration of treatment are individually determined. The initial dose is usually 20 mg every 6 hours and can be increased to 160 mg every 6 hours.
For the prophylaxis of gastric juice aspiration, general anesthesia is given at 40 mg in the evening and/or in the morning before the operation.
In renal failure, if the QC is less than thirty ml/min or the serum contains more than three mg/100 ml of creatinine, the daily dose of the drug should be reduced to 20 mg.
For the prevention of recurrent haemorrhage from the upper gastrointestinal tract, 20 mg twice a day for three to four weeks.

Use in children
It is contraindicated to children under 12 years of age.

  • Nosology Famotidine (ICD codes)
  • E16.4
  • Gastrine disruption (hypergastrinemia, Zollinger-Ellison syndrome)
  • J95.4
  • Mendelssohn syndrome
  • K21.0
  • Gastroesophageal reflux with esophagitis
  • K25
  • Stomach ulcer
  • K26
  • Duodenum ulcer
  • K27
  • Peptic ulcer
  • K29
  • Gastritis and duodenitis
  • K30
  • Functional dyspepsia (digestive disorder)
  • R12
  • Izzhoga
  • R14
  • Flatulence and related states (including bloating, burping)
  • Y45
  • Analgesic, antipyretic and anti-inflammatory agents
Active substance
Pharmacological group
Country of origin
Expiration Date
No reviews yet — your comment may be first.
All reviews 0
general rating